Influx Healthtech Earnings Call Transcript: Key Takeaways
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
- Call
- Guides 25% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
H1 FY27 revenue ₹85.4cr (+27.9%), EBITDA ₹18.3cr (+25.1%, 21.5% margin), PAT ₹12.0cr (+20.0%). Capacity expansion and wellness launches drive growth.
Influx Healthtech Ltd reported revenue from operations of ₹85.4 Cr (+27.8% YoY) and net profit of ₹12 Cr (+20.0% YoY) for H1 FY27.
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Ltd. has announced its 6th Annual General Meeting scheduled for September 18, 2026, and submitted its Annual Report for FY 2025-2026.
The Board approved the Directors' Report for FY26 and fixed the 6th AGM for September 18, 2026. They also appointed a scrutinizer for the upcoming meeting.